Effects of Escitalopram on Anxiety in Patients with Acute Coronary Syndrome: A Randomized Controlled Trial
Clinical Psychopharmacology and Neuroscience
;
: 126-131, 2017.
Artigo
em Inglês
| WPRIM
| ID: wpr-203970
ABSTRACT
OBJECTIVE:
There are no evidence-based practices for treating anxiety in patients with acute coronary syndrome (ACS). Thus, we investigated the effects of escitalopram on anxiety in this population.METHODS:
We enrolled 217 patients with ACS who met Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria for depressive disorders into a randomized double-blind placebo-controlled study. Patients received either escitalopram or placebo over a 24-week period. Anxiety symptoms were evaluated using the Hospital Anxiety and Depression Scale-anxiety subscale (HADS-A). A HADS-A score >7 was classified as an anxiety disorder. Baseline evaluations included sociodemographic and clinical characteristics, such as depressive symptoms, cardiovascular risk factors, and current cardiac status.RESULTS:
Independent of improvements in depression and without any differences in safety profiles, escitalopram treatment was significantly more efficacious in treating and reducing anxiety than placebo over a 24-week period.CONCLUSION:
Escitalopram can be recommended as an effective and safe treatment option for anxiety in patients with ACS.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Ansiedade
/
Transtornos de Ansiedade
/
Citalopram
/
Método Duplo-Cego
/
Fatores de Risco
/
Manual Diagnóstico e Estatístico de Transtornos Mentais
/
Depressão
/
Transtorno Depressivo
/
Síndrome Coronariana Aguda
Tipo de estudo:
Ensaio Clínico Controlado
/
Estudo de etiologia
/
Guia de Prática Clínica
/
Fatores de risco
Limite:
Humanos
Idioma:
Inglês
Revista:
Clinical Psychopharmacology and Neuroscience
Ano de publicação:
2017
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS